Could Mesenchymal Stem Cell-Derived Exosomes Be a Therapeutic Option for Critically Ill COVID-19 Patients?
Coronavirus disease 2019 (COVID-19) is a pandemic viral disease originated in Wuhan, China, in December 2019, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The severe form of the disease is often associated with acute respiratory distress syndrome (ARDS), and most criti...
Main Authors: | Chiara Gardin, Letizia Ferroni, Juan Carlos Chachques, Barbara Zavan |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-08-01
|
Series: | Journal of Clinical Medicine |
Subjects: | |
Online Access: | https://www.mdpi.com/2077-0383/9/9/2762 |
Similar Items
-
Mesenchymal stem cell exosomes reverse acute lung injury through Nrf-2/ARE and NF-κB signaling pathways
by: Jun Li, et al.
Published: (2020-09-01) -
Role and mechanism of angiotensin-converting enzyme 2 in acute lung injury in coronavirus disease 2019
by: Meng-Yuan Liu, et al.
Published: (2020-06-01) -
Three-dimensional culture of MSCs produces exosomes with improved yield and enhanced therapeutic efficacy for cisplatin-induced acute kidney injury
by: Jingyuan Cao, et al.
Published: (2020-05-01) -
Exosomes Derived from Mesenchymal Stem Cells Rescue Myocardial Ischaemia/Reperfusion Injury by Inducing Cardiomyocyte Autophagy Via AMPK and Akt Pathways
by: Liang Liu, et al.
Published: (2017-08-01) -
MSC-NTF (NurOwn®) exosomes: a novel therapeutic modality in the mouse LPS-induced ARDS model
by: Haggai Kaspi, et al.
Published: (2021-01-01)